Amyloid blockers may be a dead end

With few approved drugs available to treat Alzheimer disease, researchers are working on new compounds that block amyloid formation. But many potential drugs in the pipeline for the disease and other amyloid-associated illnesses may not be as promising as thought, according to a new linkurl:study;https://www.nature.com/nchembio/journal/vaop/ncurrent/abs/nchembio.65.html published today (January 27) in Nature Chemical Biology. The research, led by linkurl:Brian Shoichet;https://ucsf.edu/dbps/facu